Penumbra, Inc. (NYSE: PEN) has reported its financial results for the fourth quarter and full year ending December 31, 2025. The company revealed a revenue of $385.4 million for the fourth quarter of 2025, marking a 22.1% increase from the same period in 2024. For the full year 2025, Penumbra reported revenue of $1,403.7 million, reflecting a 17.5% increase from 2024.
In the U.S., thrombectomy revenue for the fourth quarter of 2025 was $203.1 million, representing a 12.4% increase from the same period in 2024. For the full year, U.S. thrombectomy revenue reached $771.5 million, indicating a 19.3% increase from 2024.
The company reported income from operations of $59.2 million for the fourth quarter of 2025, with an operating margin of 15.4%. For the full year 2025, income from operations was $189.2 million, with an operating margin of 13.5%.
Penumbra's net income for the fourth quarter of 2025 was $47.3 million, with an adjusted EBITDA of $79.1 million, resulting in a net income margin of 12.3% and an adjusted EBITDA margin of 20.5%. For the full year 2025, net income was $177.7 million, and adjusted EBITDA was $266.8 million, resulting in a net income margin of 12.7% and an adjusted EBITDA margin of 19.0%.
In terms of the financial outlook for the full year 2026, Penumbra will not be providing guidance due to the proposed acquisition by Boston Scientific Corporation (NYSE: BSX).
Penumbra, Inc. is recognized as the world's leading thrombectomy company, focusing on developing innovative technologies for medical conditions such as ischemic stroke, venous thromboembolism, and acute limb ischemia. The company's broad portfolio includes computer-assisted vacuum thrombectomy (CAVT) and is aimed at removing blood clots from head-to-toe with speed, safety, and simplicity, ultimately supporting healthcare providers, hospitals, and clinics in over 100 countries. Following these announcements, the company's shares moved 0.08%, and are now trading at a price of $350.78. Check out the company's full 8-K submission here.
